Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

APLT

Applied Therapeutics (APLT)

Applied Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:APLT
DateHeureSourceTitreSymboleSociété
17/05/202422h37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLTApplied Therapeutics Inc
09/05/202413h17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APLTApplied Therapeutics Inc
09/05/202413h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLTApplied Therapeutics Inc
09/05/202413h00GlobeNewswire Inc.Applied Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
07/05/202413h00GlobeNewswire Inc.Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:APLTApplied Therapeutics Inc
15/04/202413h00GlobeNewswire Inc.Applied Therapeutics Appoints Dale Hooks as Chief Commercial OfficerNASDAQ:APLTApplied Therapeutics Inc
04/04/202413h00GlobeNewswire Inc.Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024NASDAQ:APLTApplied Therapeutics Inc
28/03/202421h30GlobeNewswire Inc.Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
06/03/202413h19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APLTApplied Therapeutics Inc
06/03/202413h00GlobeNewswire Inc.Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
05/03/202423h42Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:APLTApplied Therapeutics Inc
28/02/202414h05GlobeNewswire Inc.Applied Therapeutics Announces $100 Million Private PlacementNASDAQ:APLTApplied Therapeutics Inc
28/02/202414h00GlobeNewswire Inc.Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
22/02/202420h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:APLTApplied Therapeutics Inc
15/02/202413h00GlobeNewswire Inc.Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) DeficiencyNASDAQ:APLTApplied Therapeutics Inc
13/02/202422h34Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:APLTApplied Therapeutics Inc
04/01/202422h05GlobeNewswire Inc.Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic CardiomyopathyNASDAQ:APLTApplied Therapeutics Inc
03/01/202417h20Dow Jones NewsApplied Therapeutics Shares Hit 52-Week High on Govorestat FilingsNASDAQ:APLTApplied Therapeutics Inc
03/01/202413h00GlobeNewswire Inc.Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
23/12/202302h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLTApplied Therapeutics Inc
09/11/202313h30GlobeNewswire Inc.Applied Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
02/11/202312h00GlobeNewswire Inc.Applied Therapeutics to Present at the UBS Biopharma Conference 2023NASDAQ:APLTApplied Therapeutics Inc
01/11/202312h00GlobeNewswire Inc.Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7NASDAQ:APLTApplied Therapeutics Inc
28/09/202313h00GlobeNewswire Inc.Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual MeetingNASDAQ:APLTApplied Therapeutics Inc
06/09/202317h08Dow Jones NewsApplied Therapeutics Shares Rise 11% After Pre-NDA Meeting With FDANASDAQ:APLTApplied Therapeutics Inc
06/09/202313h00GlobeNewswire Inc.Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023NASDAQ:APLTApplied Therapeutics Inc
11/08/202322h47Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APLTApplied Therapeutics Inc
10/08/202313h00GlobeNewswire Inc.Applied Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
25/07/202313h00GlobeNewswire Inc.Applied Therapeutics Provides Regulatory Update on Galactosemia ProgramNASDAQ:APLTApplied Therapeutics Inc
23/06/202322h41Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:APLTApplied Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:APLT

Dernières Valeurs Consultées

Delayed Upgrade Clock